科濟藥業－Ｂ
No. 466 Yindu Road
1st Floor Building 2 Xuhui District
Shanghai
China
86 21 6450 1828
https://www.carsgen.com
版塊: Healthcare
行業: Biotechnology
全職員工: 516
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Zonghai Li M.D., Ph.D. | Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board | 2.2M | 無 | 1974 |
| Dr. Huamao Wang Ph.D. | Co-Founder, COO & Executive Director | 2.35M | 無 | 1977 |
| Dr. Hua Jiang | Executive Director | 2.53M | 無 | 1979 |
| Dr. Hong Ma | Senior Vice President of Clinical Development | 無 | 無 | 1972 |
| Dr. Leigh Hsu | Senior Vice President of Business Development | 無 | 無 | 1971 |
| Dr. Raffaele Baffa M.D., Ph.D. | Chief Medical Officer | 無 | 無 | 1960 |
| Dr. Sylvie Peltier | Senior Vice President of Global Regulatory Affairs | 無 | 無 | 1963 |
| Mr. Wing Yat Lui | Company Secretary | 無 | 無 | 1990 |
描述
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.
公司管治
截至 無 止，科濟藥業－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
